Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
BR
Braveheart Bio, Inc. BRVE
$19.04
▼ -2.16%
($-0.42)
Open
$18.83
Prev Close
$19.46
Day Range
$18.82 – $19.50
52W Range
$16.70 – $32.00
Market Cap
$1.75B
Beta
-1.51
EPS (TTM)
$-1.25
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-08-06 |
| Shares Out. | 90,040,000 |
| Website | braveheart.bio ↗ |
| Phone | 14157076312 |
About Braveheart Bio, Inc.
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Braveheart Bio, Inc. is a publicly traded company under the ticker symbol BRVE on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-11-01)
📰 Latest News for BRVE
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call - Slideshow
Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET
Where Does Braveheart Bio (BRVE) Value Sit After AHA Data?
Braveheart Bio (BRVE), Why Is Attention Building Around It?